Study Finds FGFR1 Boosts Cholesterol Uptake in Prostate Cancer Cells

Why It Matters

Targeting the FGFR1‑SREBP2 axis could disrupt cholesterol‑driven steroidogenesis, potentially slowing progression to treatment‑resistant prostate cancer.

Key Takeaways

• FGFR1 activates SREBP2, increasing LDLR expression.
• FGFR1 loss lowers intracellular cholesterol in prostate cancer cells.
• Elevated FGFR1 correlates with aggressive prostate cancer features.
• Cholesterol fuels steroidogenesis, supporting castration‑resistant tumors.
• FGFR1 pathway presents a potential therapeutic target.

Pulse Analysis

Prostate cancer cells rely heavily on cholesterol to synthesize steroid hormones that sustain tumor growth, especially after androgen deprivation therapy. Recent work highlights FGFR1 as a master regulator that rewires lipid metabolism, channeling external LDL particles and internal synthesis pathways into a single, amplified cholesterol pool. By coupling FGFR1 signaling with SREBP2 activation, cancer cells boost LDLR expression and key biosynthetic enzymes, creating a feedback loop that fuels both membrane biogenesis and hormone production.

The mechanistic link between FGFR1 and SREBP2 involves ERK‑dependent phosphorylation, which cleaves and activates SREBP2, allowing it to translocate to the nucleus and drive transcription of cholesterol‑handling genes. This molecular cascade not only raises intracellular cholesterol but also correlates with clinical markers of disease aggressiveness, such as higher Gleason scores and earlier onset of castration‑resistant disease. The study’s computational analysis of patient datasets reinforces the biological findings, showing that tumors with elevated FGFR1 also exhibit heightened LDLR levels and poorer outcomes.

From a therapeutic perspective, the FGFR1‑SREBP2 axis offers a novel target beyond conventional androgen pathway inhibitors. Pharmacologic blockade of FGFR1 or downstream SREBP2 could starve prostate cancer cells of the cholesterol needed for steroidogenesis, potentially restoring sensitivity to hormone‑targeted therapies. Moreover, combining FGFR1 inhibitors with existing lipid‑lowering agents may produce synergistic effects, opening avenues for precision medicine strategies aimed at metabolic vulnerabilities in advanced prostate cancer.